Optimizing skin and skin structure infection outcomes: considerations of cost of care

References

• Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis. 2011;52(Suppl 7):S469–76.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry, acute bacterial skin and skin structure infections: developing drugs for treatment. 2013 Oct. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf
   Google Scholar
• Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013 May;30(13):252.
   Web of Science ®Google Scholar
• Weiss AJ, Wier LM, Stocks C, et al. Overview of emergency department visits in the United States, 2011. HCUP Statistical Brief #174. June 2014. Rockville (MD): Agency for Healthcare Research and Quality.
   Google Scholar
• Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect. 2006;134:293–299.
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291–298.
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Espinola JA, Leung DY, et al. Epidemiology of dermatitis and skin infections in United States physicians’ offices, 1993–2005. Clin Infect Dis. 2009;49:901–907.
   PubMed Web of Science ®Google Scholar
• Pakkin DJ, Camarg CA, Schuur JD. Skin infections and antibiotic stewardship: analysis of emergency department prescribing practices, 2007–2010. West J Emerg Med. 2014;15(3):282–289.
   PubMedGoogle Scholar
• Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis. 2005;5:501–513.
   PubMed Web of Science ®Google Scholar
• Peterson RA, Polgreen LA, Cavanaugh JE, et al. Increasing incidence, cost, and seasonality in patients hospitalized for cellulitis. Open Forum Infect Dis. 2017;4:ofx008.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis. 2001;32:S114–32.
   PubMed Web of Science ®Google Scholar
• Di Nubile MJ, Lipsky BA. Complicated infections of the skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53(Suppl 2):ii37–50.
   PubMedGoogle Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(2):e10–52.
   Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18.
   PubMed Web of Science ®Google Scholar
• Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim–sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374:823–832.
   PubMed Web of Science ®Google Scholar
• Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164(15):1669–1674.
   PubMedGoogle Scholar
• Orbactiv® [package insert]. Parsippany (NJ): The Medicines Company; 2014.
   Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683–1693.
   PubMed Web of Science ®Google Scholar
• Agarwal R et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. (2017), DOI:10.1016/j.cmi.2017.08.028
   Web of Science ®Google Scholar
• Chuan J, Zhang Y, He X, et al. Systematic review and meta-analysis of the efficacy and safety of telavancin for treatment of infectious disease: are we clearer? Front Pharmacol. 2016;7:330.
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Barriere SL, Nicolau DP, et al. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008;28(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2011;55(1):421–425.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007;60(2):300–311.
   PubMed Web of Science ®Google Scholar
• Huang X, Beresford E, Lodise T, et al. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: budget impact analysis from a hospital perspective. Am J Health Syst Pharm. 2013;70(12):1057–1064.
   PubMed Web of Science ®Google Scholar
• Karve S, Hackett J, Levinson J, et al. Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections. J Comp Eff Res. 2016 Jul;5(4):393–405.
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect. 2005;11:95–100.
   PubMed Web of Science ®Google Scholar
• Dalvance® [package insert]. Chicago (IL): Durata Therapeutics US Limited; 2016.
   Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551.
   PubMed Web of Science ®Google Scholar
• Bouza E, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018. doi: 10.1016/j.ijantimicag.2017.11.008
   Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of oxazolidinone TR-700 against linezolid-susceptible and – resistant staphylococci and enterococci. J Antimicrob Chemother. 2009;63:713–715.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(2):864–871.
   PubMed Web of Science ®Google Scholar
• Sivextro® [package insert. Whitehouse Station (NJ): Merck Sharp & Dohme Corp.; 2015.
   Google Scholar
• Flanagan S, Bartizal K, Fang E, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57(7):3060–3066.
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Petrakis I, Ollandezos M, et al. Antibacterial treatment of methicillin-resistant staphylococcus aureus complicated skin and soft tissue infections: a cost and budget impact analysis in Greek hospitals. Infect Dis Ther. 2014;3(2):257–268.
   PubMedGoogle Scholar
• Barron J, Turner R, Jaeger M, et al. Comparing the use of intravenous antibiotics under the medical benefit with the use of oral antibiotics under the pharmacy benefit in treating skin and soft tissue infections. Manag Care. 2012;21(9):44–52.
   PubMedGoogle Scholar
• Menzin J, Marton JP, Meyers JL, et al. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010;38(1):44–49.
   PubMed Web of Science ®Google Scholar
• Schurmann D, Sorensen SV, De Cock E, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009;10(1):65–79.
   PubMed Web of Science ®Google Scholar
• De Cock E, Sorensen S, Levrat F, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect. 2009;39(5):330–340.
   PubMed Web of Science ®Google Scholar
• Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425–428.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis. 2012;54(Suppl 3):S203–13.
   PubMed Web of Science ®Google Scholar
• Corey GR, Arhin FF, Wikler MA, et al. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2016;48(5):528–534.
   PubMed Web of Science ®Google Scholar
• Jensen IS, Lodise TP, Fan W, et al. Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: a US hospital budget impact analysis. Clin Drug Investig. 2016;36(2):157–168.
   PubMed Web of Science ®Google Scholar
• Anastasio PJ, Wolthoff P, Galli A, et al. Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther. 2017;6(1):115–128.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fan W, Sulham KA. Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations. Clin Ther. 2016;38(1):136–148.
   PubMed Web of Science ®Google Scholar
• Jensen IS, Wu E, Fan W, et al. Use of oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: a U.S. payer budget impact analysis. J Manag Care Spec Pharm. 2016;22(6):752–764.
   PubMedGoogle Scholar
• Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol. 2017;57(3):328–335.
   PubMed Web of Science ®Google Scholar
• Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017 Dec 1;72(12):3471–3480.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Amin A, Ford WT, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–519.
   PubMed Web of Science ®Google Scholar
• Linder KE, Nicolau DP, Nailor MD. Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. Hosp Pract (1995). 2017;45(1):9–15.
   PubMedGoogle Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57:7–13
   Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366(9498):1695–1703.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Available from: https://www.cdc.gov/drugresistance/threat-report-2013/
   Google Scholar
• Tascini C, Lipsky BA, Iacopi E, et al. KPC-producing Klebsiella pneumonia rectal colonization is a risk factor for mortality in patients with diabetic foot infections. Clin Microbiol Infect. 2015;21:790.
   PubMed Web of Science ®Google Scholar
• Guillamet CV, Kollef MH. How to stratify patients at risk for resistant bugs in skin and soft tissue infections? Curr Opin Infect Dis. 2016;29(2):116–123.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–674.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585–1591.
   PubMed Web of Science ®Google Scholar
• Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013;13:252–262.
   PubMed Web of Science ®Google Scholar
• Summamen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft tissue infections: a comparison of infections and intravenous drug users and individuals with no history of drug use. Clin Infect Dis. 1995;20:S279–82.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Amil RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11:928–930.
   PubMed Web of Science ®Google Scholar
• Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J Med Microbiol. 2012;61:1179–1193.
   PubMed Web of Science ®Google Scholar
• Jones GR, Cumming DV, Honeywell G, et al. How is income generated by outpatient parenteral antibiotic treatment (OPAT) in the UK? Analysis of payment tariffs for cellulitis. J Antimicrob Chemother. 2015;70(4):1236–1240.
   PubMed Web of Science ®Google Scholar
• Nazarko L. Avoiding admission and facilitating early discharge through OPAT. Br J Nurs. 2014;23(14):S30–6.
   PubMedGoogle Scholar
• Labreche MJ, Lee GC, Attridge RT, et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med. 2013 Sep–Oct;26(5):508–517.
   PubMed Web of Science ®Google Scholar
• Frei CR, Miller ML, Lewis JS 2nd, et al. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CAMRSA) skin infections. J Am Board Fam Med. 2010;23(6):714–719.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Eisenberg DF, Fang C, et al. Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S. PLoS One. 2013 Apr 10;8(4):e60057.
   PubMed Web of Science ®Google Scholar
• Ektare V, Khachatryan A, Xue M, et al. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092–1101.
   PubMed Web of Science ®Google Scholar
• LaPensee K, Fan W Economic burden of hospitalization with antibiotic treatment for ABSSSI in the US: an analysis of the Premier Hospital Database. 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Washington (DC); 2012
   Google Scholar
• Sulham K, LaPensee K, Fan W, et al. Severity and costs of acute bacterial skin and skin structure infections by treatment setting: an application of the Eron classification to a real-world database. Value Health. 2014;17(3):A282.
   Web of Science ®Google Scholar
• Bosso JA, Casapao AM, Edwards J, et al. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. Hosp Pract (1995). 2016 Oct;44(4):183–189.
   PubMedGoogle Scholar
• Jain SR, Hosseini-Moghaddam SM, Dwek P, et al. Infectious diseases specialist management improves outcomes for outpatients diagnosed with cellulitis in the emergency department: a double cohort study. Diagn Microbiol Infect Dis. 2017;87(4):371–375.
   PubMed Web of Science ®Google Scholar